Delivery Order SPE2DB22D1103-SPE2DB25FH3M6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Rexulti 1 mg tablets (30-count package) valued at $9,576.43 under a firm fixed-price contract. This non-set-aside award represents a competitively awarded delivery order that will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) with a ceiling value of $9,967.07. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 8, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Rexulti 1 mg tablets (30-count units) valued at $5,136.24. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. The contract is scheduled for completion by August 7, 2025, and represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $18,081.18, for 30-count tablets of Rexulti 1 mg on September 15, 2025, with completion scheduled for September 16, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a single transaction under the company's broader pharmaceutical supply relationship with the federal government. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Rexulti 2 mg tablets (30-count units) valued at $12,358.69. This is a firm fixed price, non-set-aside delivery order with a completion date of September 16, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's extensive role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a $5,123.39 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Rexulti 1 mg tablets (30-count units). The contract, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by September 22, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a Delivery Order valued at $2,783.93 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The order represents a single transaction under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on August 13, 2025, with a ceiling value of $1,002.23 and firm fixed pricing. This delivery order is non-set-aside and represents a competitive award to the pharmaceutical distributor, with an ultimate completion date of August 14, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $11,040.23 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) on September 25, 2025, with completion expected by September 26, 2025. The contract employs firm fixed price pricing and represents a non-set-aside competitive award. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a leading...
- The Defense Logistics Agency awarded a delivery order valued at $13,026.20 to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of Rexulti 3 mg tablets (30-count units). This firm fixed-price, non-competitive delivery order is scheduled for completion by June 30, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs. This delivery order is...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH3M6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,446.66 to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The order is scheduled for completion by September 29, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is well-positioned as a critical federal vendor supplying brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.4k | 9/26/25 |